Showing 2821-2830 of 4166 results for "".
- Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of RPhttps://modernod.com/news/endogena-therapeutics-completes-dose-escalation-in-the-phase-12a-clinical-trial-of-ea-2353-for-the-treatment-of-retinitis-pigmentosa/2481511/Endogena Therapeutics announced that the dose-escalation stage of its phase 1/2a study of EA-2353 in retinitis pigmentosa (RP) has been successfully completed. No clinically relevant or dose-limiting adverse events were identified after repeated intravitreal injections. Given the positive sa
- Clearside Biomedical Announces Positive Data on CLS-AX OASIS Clinical Trial and Use of SCS Microinjectorhttps://modernod.com/news/clearside-biomedical-announces-positive-data-on-cls-ax-oasis-clinical-trial-and-use-of-scs-microinjector/2481423/Clearside Biomedical announced data from presentations delivered at the Angiogenesis, Exudation, and Degeneration 2023 meeting and The Macula Society 46th Annual Meeting. “The promising durability data from our OASIS clinical trial continues to garner si
- Atsena Therapeutics to Present Positive Phase 1/2 Clinical Trial Data of ATSN-101 for the Treatment of GUCY2D-Associated LCA1https://modernod.com/news/atsena-therapeutics-to-present-positive-phase-12-clinical-trial-data-of-atsn-101-for-the-treatment-of-gucy2d-associated-lca1/2481394/Atsena Therapeutics announced that positive interim data from the ongoing phase 1/2 clinical trial of ATSN-101 will be presented at the 46th Annual Macula Society Meeting, which is being held February 15-18 in Miami. This is an encore presentation of data that were presented as a l
- Topcon Achieves ISO 27001 Certification of its Harmony RS Clinical Data Management Systemhttps://modernod.com/news/topcon-achieves-iso-27001-certification-of-its-harmony-rs-clinical-data-management-system/2481354/Topcon Healthcare has obtained ISO 27001 certification of its Harmony RS Clinical Data Management System. ISO 27001 is a globally recognized standard for the establishment and certification of an information security management system (ISMS). The standard speci
- MediPrint Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Assethttps://modernod.com/news/mediprint-ophthalmics-announces-it-has-initiated-its-sight-2-phase-2b-clinical-study-for-its-lead-asset/2481231/MediPrint Ophthalmics announced it has initiated its SIGHT-2 dose-finding phase 2b study for its proprietary drug-eluting contact lens for glaucoma. This is the second study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating
- Aramis Biosciences Completes Enrollment of its Phase 2 Clinical Trial Evaluating A197 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aramis-biosciences-completes-enrollment-of-its-phase-2-clinical-trial-evaluating-a197-for-the-treatment-of-dry-eye-disease/2481219/Aramis Biosciences announced the completion of enrollment in its phase 2 proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease. “We are very pleased to have completed the enrollment of our phas
- Neurophth Announces First Patient Dosed in Phase 3 Clinical Trial for the Gene Therapy Treatment of LHONhttps://modernod.com/news/neurophth-announces-first-patient-dosed-in-phase-3-clinical-trial-for-the-gene-therapy-treatment-of-lhon/2481126/Neurophth Therapeutics announced that the first patient has been dosed in phase 3 clinical trial for the treatment of Leber hereditary optic neuropathy (LHON). Neurophth is conducting a phase 1/2/3, multicenter, two-part study aimed at evaluating the safety, tolerability, and effic
- Iveric Bio Announces Positive Topline Data from Zimura GATHER2 Phase 3 Clinical Trial in Geographic Atrophyhttps://modernod.com/news/iveric-bio-announces-positive-topline-data-from-zimura-gather2-phase-3-clinical-trial-in-geographic-atrophy/2481062/Iveric bio announced positive topline results from GATHER2, the company’s second phase 3 clinical trial of Zimura (avacincaptad pegol), a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA). GATHER2 met its prespecified primary endpoint of mean r
- OcuTerra Therapeutics Announces First Patient Dosed in OTT166 Phase 2 DR:EAM Clinical Trial for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-therapeutics-announces-first-patient-dosed-in-ott166-phase-2-dream-clinical-trial-for-diabetic-retinopathy/2481009/OcuTerra Therapeutics announced that the first patient was dosed in its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating OTT166 in adult patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) or mild proli
- Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-completes-dosing-in-oasis-phase-12a-clinical-trial-of-cls-ax-in-wet-amd-patients/2480989/Clearside Biomedical announced today completion of dosing in Cohorts 3 and 4 of OASIS, its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a US-based, multicen